Rylo Health review

What it is

Rylo Health (Rylo Health LLC) is a telehealth platform selling compounded GLP-1 medications alongside a longevity peptide line. Its available products are sermorelin, described as supporting growth hormone, sleep and recovery; NAD⁺, described as a coenzyme supporting cellular energy and metabolic function; and glutathione, described as an antioxidant. Three further products — GHK-Cu, MOTS-c and a Pulse Stack combining CJC-1295 and ipamorelin — are listed as coming soon rather than orderable. Clinical care is stated to run through Lone Star Virtual Health PLLC across all fifty states, with prescriptions filled by VialsRX in Houston, Texas.

How it works

Asynchronous telehealth into a prescription filled by a single named pharmacy, with the all-fifty-states claim stated twice on the site, in a services FAQ and in a clinical-care FAQ. The disclosure quality is the story here. A pharmacy with a full street address and a phone number is a pharmacy you can call and ask about a batch; "a US-licensed compounding pharmacy" is not. A named medical group with a PLLC suffix is a registered entity you can look up; "board-certified physicians in your state" is not. Very little of this board clears both bars, and Rylo clears them without being asked. Cancellation matches: no contracts, no cancellation fees, handled from the patient portal or by messaging support. Three things pull the other way. It claims no LegitScript certification and displays no seal. It publishes no refund policy beyond the no-cancellation-fee line, so what happens if a shipment arrives damaged or late is unstated. And its peptide shelf is smaller in practice than it looks — GHK-Cu, MOTS-c and the CJC-1295 + ipamorelin stack are advertised as coming soon, which means three of six tiles are not products yet.

Pricing transparency

Structurally honest in a way that is worth naming. Each peptide tile leads with a per-month figure derived from the quarterly prepay and then states the month-to-month rate beside it: sermorelin $183/mo as $549 every three months, or $249 monthly; NAD⁺ the same $183/$549 pair against $219 monthly; glutathione $133/mo as $399 quarterly, or $149 monthly. Most services in this category publish only the lower figure and let you find the higher one at checkout. We publish the month-to-month rate, because it is the price of being able to stop. Its GLP-1 side follows the same pattern with an important asterisk of its own: the headline $100 semaglutide and $160 tirzepatide rates are stated as a First 20 promotional rate capped at twenty patients, with standard rates of $149 and $249 — and the site publishes both, which is again more than most manage. None of those GLP-1 figures is a peptide price. What is not stated anywhere is the dose, vial size or injection frequency behind any peptide figure, so ask what a month actually contains before comparing it against another service's number.

Branded vs compounded

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. The dispensing pharmacy is named, which is the disclosure that matters most for an injectable, and compounded sterile products are still not reviewed by the FDA for purity and potency the way approved drugs are. On the evidence, the three orderable products sit on three different tiers. Sermorelin is a GHRH analogue acting on a real, well-characterised growth-hormone axis, with human outcome data that thins out quickly past short-term IGF-1 movement. Injected NAD⁺ has no controlled human outcome trials at all — the one human intravenous study was a pharmacokinetic pilot showing infused NAD⁺ clears plasma quickly — while the NAD⁺ forms with human trial data are the oral precursors NR and NMN, which raise a blood level rather than demonstrate an outcome. Injectable glutathione has essentially no controlled human outcome data behind the antioxidant, immunity and skin claims attached to it. The three coming-soon items would extend that pattern rather than improve it: GHK-Cu and MOTS-c have essentially no controlled human outcome data, and CJC-1295 with ipamorelin is another growth-hormone secretagogue combination. Individual results vary.

Pros and watch-outs

The evidence behind what Rylo Health prescribes

We grade the molecules, not the marketing. Here is what the human data actually shows for each thing on their menu.

• Sermorelin: a real GHRH drug, read against the anti-aging pitch

  An approved growth-hormone-releasing analog with a pediatric track record — and a longevity case built more on biomarkers than outcomes.

• NAD injections: how to get them near you or online, and what the evidence really says

  Subcutaneous NAD+ injections are sold as a cheaper, at-home alternative to the IV drip — via “near me” clinics or telehealth shipped to your door. They’re compounded, not FDA-approved, and have no outcome trials; oral NR/NMN precursors are the route with the human data.

• NAD+ precursors (NR and NMN): what the human trials actually show

  They raise NAD+ and look safe short-term — but human evidence is surrogate-marker level, and no trial shows they extend healthspan.

• Glutathione: the master antioxidant, and where the evidence actually is

  Oral glutathione really does raise your body stores (a 6-month RCT proved it) — but the longevity and detox claims are unproven, skin-lightening is modest, and IV glutathione is the most marketed, least evidenced route. The precursors may be the smarter bet.

How Rylo Health compares

A few alternatives worth a look, depending on what you’re optimizing for.

• RXRxPepsDirect

  NAD⁺ buyers who want the milligrams stated so they can compare cost per dose

  See RxPepsDirect →
• PRPreventiveMD

  NAD⁺ at a published all-in price from a platform that tells you up front whether it can treat you

  See PreventiveMD →
• PTPrecision Telemed

  NAD⁺ from a platform whose prescribers and pharmacies you can independently verify

  See Precision Telemed →